STOCK TITAN

Predictive Oncology Inc - POAI STOCK NEWS

Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.

Overview

Predictive Oncology Inc (NASDAQ: POAI) is an innovative, AI-driven biomedical platform specializing in personalized cancer therapies and precision oncology. The company integrates cutting-edge artificial intelligence, machine learning, and bioinformatics with clinical data to revolutionize drug discovery and biomarker prediction. By harnessing AI-driven strategies, the firm aims to enhance the accuracy of treatment selection and improve patient outcomes in the evolving landscape of cancer research.

Business Model and Operations

At its core, Predictive Oncology Inc operates across multiple strategic segments designed to address distinct facets of oncology research and clinical laboratory work. The firm has built proprietary capabilities across several domains:

  • Pittsburgh Segment: This division is focused on comprehensive data analytics through a proprietary biobank containing over 150,000 tumor samples collected over decades. Utilizing an in-house AI/ML platform, the Pittsburgh segment not only generates drug response predictions but also builds advanced 3D cell culture models to simulate tumor behavior in controlled environments.
  • Birmingham Segment: Focused on contract research, this segment provides essential support in solubility testing, stability studies, and protein production. These foundational services contribute to the broader research ecosystem by allowing efficient refinement of biologic formulations.
  • Eagan Segment: With the production of the FDA-cleared STREAMWAY System, this segment offers automated medical fluid waste management and patient-to-drain fluid disposal solutions. It represents the segment with the highest revenue contribution and underscores the company’s commitment to clinical excellence and regulatory compliance.

Technological Innovations

Predictive Oncology stands out due to its deep technological integration. The company leverages its robust AI platform to process vast datasets including multi-omic, genomics, digitized pathology, and phenotypic profiles. Key technological highlights include:

  • AI/ML Platform: Known for its predictive power, the PEDAL platform has been scientifically validated to forecast tumor response to various drug compounds with remarkable accuracy. This capability allows practitioners and researchers to fine-tune therapeutic approaches early in the drug development process.
  • Biobank and Data Repository: The company’s expansive repository, enriched through decades of clinical and laboratory data, forms the backbone of its research efforts. The biobank includes cryopreserved tumor samples and thousands of pathology slides, ensuring that predictive models have a rich data foundation.
  • 3D Cell Culture Models: Utilizing state-of-the-art 3D cell culture techniques, the company creates patient-derived tumor models that more accurately replicate in vivo conditions. This innovation supports drug screening and personalized medicine by capturing the intricacies of tumor heterogeneity.
  • Clinical Lab Capabilities: With its CLIA-certified laboratories, Predictive Oncology maintains high standards of diagnostic testing and validation, ensuring that its data sets are both clinically reliable and reproducible over long periods.

Industry Position and Market Significance

Operating at the intersection of biotechnology and digital health, Predictive Oncology has secured a unique position within the precision medicine market. Its integration of AI-driven analytics with a comprehensive clinical asset base allows the company to contribute meaningfully to drug discovery efforts in oncology. This integration enables the identification of novel biomarkers and supports de-risking strategies in drug development by addressing patient heterogeneity from the earliest stages of testing.

The company's diverse portfolio not only provides robust support to academic and industrial partners but also addresses critical needs in the competitive landscape of personalized cancer therapy. Its collaborative initiatives with key stakeholders in the pharmaceutical, diagnostic, and biotech sectors further underscore its commitment to advancing cancer treatment research.

Key Attributes and Value Proposition

Predictive Oncology Inc is recognized for its:

  • Comprehensive Data Assets: A vast collection of clinically validated tumor samples and pathology slides enables precise modeling of drug responses and biomarker discovery, offering an expansive resource for precision oncology research.
  • Technological Integration: The seamless integration of AI, machine learning, and clinical experimentation positions the company as a bridge between advanced data analytics and clinical applications in oncology.
  • Regulatory and Clinical Excellence: With a wholly owned CLIA lab and FDA-cleared systems, the company adheres to rigorous clinical standards, ensuring the reproducibility and accuracy of its data and research outcomes.
  • Broad Industry Collaborations: Through partnerships with pharmaceutical companies, biotech firms, and research institutions, Predictive Oncology leverages diverse expertise to elevate the standard of personalized cancer therapy research.

Scientific and Research Applications

Scientific inquiry at Predictive Oncology is driven by a commitment to deep data analysis and clinical validation. The company's research scope spans:

  • Biomarker Discovery: By utilizing multi-omic data and retrospective analyses, the company identifies key features that inform patient outcomes and drug efficacy. This approach supports the development of clinical decision support tools and personalized treatment protocols.
  • Drug Repurposing and Screening: Employing high-throughput AI models, the company efficiently evaluates both existing and novel compounds. Its data-driven methods allow for rapid iterative testing that reduces the time required for preliminarily assessing drug candidates.
  • Patient-Derived Tumor Models: The creation of advanced 3D cell culture systems grounded in live cell data paves the way for more physiologically relevant examination of drug responses, ultimately contributing to tailored therapeutic strategies.

Operational Excellence and Data Integrity

Reliability and precision are at the heart of Predictive Oncology’s operational framework. Every step of the process, from sample collection and data curation in its biobank to AI model validation in CLIA-certified labs, is done with stringent quality controls. This unwavering emphasis on data integrity supports both the scientific research and the clinical applications of the company’s offerings. Detailed longitudinal records and stringent testing protocols ensure that historical data remains robust and relevant, a critical factor when building predictive models that support personalized therapy decisions.

Conclusion

In summary, Predictive Oncology Inc represents a convergence of advanced data science, artificial intelligence, and clinical expertise in oncology. Its multidimensional approach—spanning AI-driven drug discovery, personalized treatment profiling, and rigorous clinical validation—positions the company as a vital contributor to innovation in personalized cancer therapy research. With comprehensive resources that include an extensive biobank, state-of-the-art laboratory capabilities, and a diversified operational structure, the company provides a rich, data-driven foundation for transforming how cancer is diagnosed and treated. This informed, methodical integration of technology and clinical science not only fosters advancements in the field but also underscores the company’s contribution to shaping future standards in precision medicine and oncology research.

Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) announces the appointment of Raymond F. Vennare as Chief Executive Officer and Chairman of the Board, effective November 1. Vennare, a board member since September 2021, is recognized for his extensive experience in biotechnology and bioinformatics. He aims to lead the company's expansion in oncology drug development through AI-driven solutions and a vast biobank of over 150,000 tumors. His leadership is expected to enhance Predictive Oncology's capabilities in the pharmaceutical sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) has announced significant advancements to enhance its services for pharmaceutical and biotech clients. The opening of a Good Manufacturing Practices (GMP) lab will facilitate the transition from pre-clinical drug development to IND qualification, enabling faster entry to phase 1 clinical trials. Additionally, Dr. Kamal Egodage joins as a strategic advisor to lead formulation development and sales strategies, contributing to the launch of innovative products, including a new static light scattering instrument and a high-capacity endotoxin removal column.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.89%
Tags
none
-
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) announces the retirement of CEO and Chairman J. Melville Engle, effective October 31, 2022. Engle, 72, has been pivotal since joining the board in 2016, becoming CEO in 2021. Under his leadership, the company expanded its oncology drug development solutions. Engle’s notable achievement includes the acquisition of zPREDICTA to enhance 3D tumor model production for drug development. The company is working on a succession plan for new leadership to drive future growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.89%
Tags
none
Rhea-AI Summary

Predictive Oncology Inc. (NASDAQ: POAI) reported Q2 2022 results showcasing a solid financial position with cash and equivalents increasing to $28 million, a 12% rise from the previous quarter. The company recognized $0.4 million in net sales revenue, up 6% year-over-year, with an improved gross profit margin of 64%. However, the company faced a $7.2 million non-cash goodwill impairment. Key developments included the launch of the PeDAL AI product and the appointment of Dr. Julia Kirshner as Chief Scientific Officer, aimed at enhancing product integration and growth opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.18%
Tags
-
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) announced the appointment of Julia Kirshner, Ph.D., as Chief Scientific Officer, effective August 1, 2022. Dr. Kirshner, currently Senior Vice President and President of zPREDICTA, will oversee the scientific processes for the company’s oncology drug development solutions. She is tasked with driving product strategies, leading the establishment of a scientific advisory board, and consolidating the TumorGenesis division in Pittsburgh by September 30, 2022. Dr. Kirshner’s extensive experience in drug development and her academic background positions her to enhance POAI’s R&D capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
management
-
Rhea-AI Summary

Predictive Oncology (Nasdaq: POAI) has successfully concluded two concurrent offerings, generating gross proceeds of approximately $7.2 million. The first offering involved issuing 3,837,280 shares at $0.60 per share, totaling around $2.3 million. In a concurrent private placement, warrants for the same number of shares were issued. The second offering included 8,162,720 shares at $0.60, raising about $4.9 million. The amended warrants had their exercise price reduced to $0.70. Proceeds will primarily be utilized for working capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.23%
Tags
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) announced it has entered into agreements with institutional investors to raise approximately $7.2 million through two concurrent offerings. The first offering involves 3,837,280 shares at $0.60 per share, raising about $2.3 million. The second offering will sell 8,162,720 shares, also at $0.60 per share, totaling around $4.9 million. Additionally, existing warrants will be amended to have a reduced exercise price of $0.70. Proceeds are intended for working capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.78%
Tags
-
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) reported Q1 2022 revenue of $314,568, up from $280,317 in Q1 2021, driven by a 6% increase in the Skyline segment and initial sales from zPREDICTA. The company reduced its loss per share to $0.05 from $0.11 year-over-year. Cash and equivalents stood at $25 million with no long-term debt. While general and administrative expenses decreased to $2.4 million, operating expenses rose due to zPREDICTA's staffing. The gross profit margin remained steady at 65%. The firm is optimistic about its commercialization efforts for Helomics and zPREDICTA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
-
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) has appointed Theresa Ferguson as Senior Director of Marketing. This role is pivotal as the company moves toward commercializing its AI-driven technologies aimed at developing personalized cancer therapies. Ferguson's expertise in marketing and public relations will support and guide strategic initiatives to enhance the company's market presence and profitability. CEO J. Melville Engle emphasizes this appointment as a step towards achieving sales and marketing traction in core markets, reflecting the company’s commitment to business growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
Rhea-AI Summary

Predictive Oncology (POAI) reported its financial results for 2021, revealing revenue of $1.4 million, an increase from $1.25 million in 2020. The company strengthened its balance sheet with $55 million raised, and a significant acquisition of zPREDICTA, enhancing its drug discovery capabilities. However, it recorded a net loss of $19.7 million, down from $25.9 million in 2020, with accumulated deficits reaching $128 million. Operational expenses rose due to payroll and cloud computing costs, while goodwill impairment from previous acquisitions impacted financial metrics, emphasizing the need for sustainable growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.81%
Tags

FAQ

What is the current stock price of Predictive Oncology (POAI)?

The current stock price of Predictive Oncology (POAI) is $1.34 as of April 4, 2025.

What is the market cap of Predictive Oncology (POAI)?

The market cap of Predictive Oncology (POAI) is approximately 9.2M.

What is the core focus of Predictive Oncology Inc?

Predictive Oncology Inc specializes in using artificial intelligence to drive personalized cancer therapies, biomarker discovery, and advanced drug discovery processes through its extensive clinical and molecular data assets.

How does the company generate revenue?

The company operates through distinct segments including AI-driven drug discovery and 3D tumor modeling, contract research in solubility and stability studies, and the production of FDA-cleared clinical lab systems, each contributing to its diversified revenue streams.

What are the primary technological innovations employed by the company?

Its innovations include a proprietary AI/ML platform for predictive modeling, a vast biobank of tumor samples and pathology slides, and advanced 3D cell culture models that better simulate the in vivo environment for accurate drug response testing.

How does Predictive Oncology contribute to personalized medicine?

The company leverages its integrated approach by combining large-scale clinical data with AI analytics, enabling the development of predictive models that tailor cancer therapies to individual patient profiles and improve treatment outcomes.

What competitive advantages does Predictive Oncology hold in its industry?

Its competitive edge lies in its comprehensive clinical and molecular dataset, validated AI platform, and integrated laboratory capabilities. These aspects enable robust drug response predictions and biomarker discovery, setting it apart in the personalized oncology landscape.

How does the company ensure data integrity and clinical reliability?

Predictive Oncology maintains high standards through its CLIA-certified laboratories and rigorous quality control measures across its biobank. This ensures the reproducibility and accuracy of its predictive models and clinical data.

Who are the primary customers and partners of Predictive Oncology?

The company collaborates with academic institutions, pharmaceutical companies, and biotech firms that require advanced AI tools and clinically validated data for drug discovery, personalized therapy research, and biomarker development.

How does the company address challenges in drug discovery?

By integrating patient heterogeneity early in its AI-driven screening processes and utilizing advanced 3D cell culture methods, Predictive Oncology mitigates common challenges such as late-stage clinical trial failures and enhances the predictability of drug responses.
Predictive Oncology Inc

Nasdaq:POAI

POAI Rankings

POAI Stock Data

9.16M
7.10M
1.55%
3.34%
7.11%
Medical Instruments & Supplies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
PITTSBURGH